WallStSmart

Eli Lilly and Company (LLY)vsOutset Medical Inc (OM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 54454% more annual revenue ($65.18B vs $119.48M). LLY leads profitability with a 31.7% profit margin vs -68.3%. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06

OM

Hold

37

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 6/9Altman Z: -5.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

OMUndervalued (+83.6%)

Margin of Safety

+83.6%

Fair Value

$27.66

Current Price

$4.36

$23.30 discount

UndervaluedFair: $27.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$760.43B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

OM1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.0x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
31.5x2/10

Trading at 31.5x book value

OM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$81.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.2%2/10

ROE of -106.2% — below average capital efficiency

Revenue GrowthGrowth
-2.0%2/10

Revenue declined 2.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bull Case : OM

The strongest argument for OM centers on Price/Book.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Bear Case : OM

The primary concerns for OM are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

LLY profiles as a growth stock while OM is a turnaround play — different risk/reward profiles.

OM carries more volatility with a beta of 1.96 — expect wider price swings.

LLY is growing revenue faster at 42.6% — sustainability is the question.

LLY generates stronger free cash flow (678M), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 37/100), backed by strong 31.7% margins and 42.6% revenue growth. OM offers better value entry with a 83.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Outset Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. The company is headquartered in San Jose, California.

Want to dig deeper into these stocks?